Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Advances in umbilical cord blood cell therapy: the present and the future
KTH, School of Engineering Sciences (SCI), Applied Physics.
Show others and affiliations
2017 (English)In: Expert Opinion on Biological Therapy, ISSN 1471-2598, E-ISSN 1744-7682, Vol. 17, no 6, 691-699 p.Article, review/survey (Refereed) Published
Abstract [en]

Introduction: Umbilical cord blood (UCB), previously seen as medical waste, is increasingly recognized as a valuable source of cells for therapeutic use. The best-known application is in hematopoietic stem cell transplantation (HSCT), where UCB has become an increasingly important graft source in the 28 years since the first umbilical cord blood transplantation (UCBT) was performed. Recently, UCB has been increasingly investigated as a putative source for adoptive cell therapy. Areas covered: This review covers the advances in umbilical cord blood transplantation (UCBT) to overcome the limitation regarding cellular dose, immunological naivety and additional cell doses such as DLI. It also provides an overview regarding the progress in adoptive cellular therapy using UCB. Expert opinion: UCB has been established as an important source of stem cells for HSCT. Successful strategies to overcome the limitations of UCBT, such as the limited cell numbers and naivety of the cells, are being developed, including novel methods to perform in vitro expansion of progenitor cells, and to improve their homing to the bone marrow. Promising early clinical trials of adoptive therapies with UCB cells, including non-immunological cells, are currently performed for viral infections, malignant diseases and in regenerative medicine.

Place, publisher, year, edition, pages
Taylor & Francis, 2017. Vol. 17, no 6, 691-699 p.
Keyword [en]
adoptive cell therapy, clinical trials, Cord blood transplantation, HLA, lymphocytes
National Category
Hematology
Identifiers
URN: urn:nbn:se:kth:diva-209592DOI: 10.1080/14712598.2017.1316713ISI: 000402979500004Scopus ID: 2-s2.0-85019123668OAI: oai:DiVA.org:kth-209592DiVA: diva2:1113990
Funder
Swedish Research Council, 2014-1839Swedish Childhood Cancer Foundation, KP2016-0027
Note

QC 20170622

Available from: 2017-06-22 Created: 2017-06-22 Last updated: 2017-07-03Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Vanherberghen, BrunoUhlin, Michael
By organisation
Applied PhysicsCellular Biophysics
In the same journal
Expert Opinion on Biological Therapy
Hematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 5 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf